At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top California based Director operating in the Biotechnology space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Kristina Burow
Managing Director of ARCH Venture Partners
Kristina Burow is a Managing Director with ARCH Venture Partners. Kristina Burow is focused on the creation and development of biotechnology, pharmaceutical and agbiotechnology companies.
Follow Kristina Burow:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Lina Nilsson
Senior Director, Data Science Product of Recursion Pharmaceuticals
Follow Lina Nilsson:
About Recursion Pharmaceuticals: Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Mariam Iqbal
Director Of Procurement of AstraZeneca
Follow Mariam Iqbal:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Neil Poloso
Executive Director, Biological Research of Allergan
Follow Neil Poloso:
About AbbVie, Allergan: Allergan is a global pharmaceutical company.
Tory Brady
Director of Product Engineering of Allergan
Tory Brady’s passion is building software with a keen eye on the customer and the jobs they’re hiring a product to do in their lives. He loves when beautiful design, performant code and comprehensive data intersect. He’s had a fruitful career as a Software Engineer, working for a variety of technology start-ups. Now Tory is applying these learned start-up methodologies to Allergan’s medical aesthetics business as they work to revitalize the digital relationship with their consumers.
Follow Tory Brady:
About Allergan: Allergan is a global pharmaceutical company.
Xue Snow Ge
Sr. Director, Clinical Pharmacology of Nektar Therapeutics
Xue Snow Ge serves as the Senior Director of Clinical Pharmacology at Nektar Therapeutics. She also serves as an Advisor at Berkeley SkyDeck.
Follow Xue Snow Ge:
About Nektar Therapeutics: Nektar Therapeutics develops therapeutics based on its advanced polymer conjugate chemistry technology platform.
John Melo
Director, President & Chief Executive Officer of Amyris
John Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum) most recently as President of U.S. fuels operations where he successfully led a business transformation and significantly improved the financial performance. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment; Senior Advisor for e-business strategy to Lord Browne, BP group chief executive; and Director of global brand development. In this last role, he helped develop the “Helios” re-branding effort. Before joining BP, Mr. Melo was with Ernst & Young. Mr. Melo currently serves on the board of directors of Renmatix Inc., serves on the board of directors of BayBio, serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. When not working on the mission of making sustainable chemistry mainstream or championing the eradication of malaria, John enjoys skiing, reading and time with his family on the island of Pico in the Azores, his childhood home.
Follow John Melo:
About Amyris: Amyris Biotechnologies specializes in creating renewable products focusing on fuels and chemicals.
Jason Coloma
President, Chief Mazer; Director of Maze Therapeutics
Dr. Jason Coloma is the CEO of Maze Therapeutics. Prior to his appointment to CEO, he was Maze’s interim chief operating officer and a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch of the company. As a venture partner at Third Rock, Jason focused on new company creation, and held interim chief business officer roles at portfolio companies insitro and Celsius Therapeutics. Prior to Third Rock, Jason was senior vice president and chief business officer at Corvus Pharmaceuticals. Previously, he held a number of roles at Roche, including vice president & global therapeutic area head of oncology and cancer immunotherapy partnering. Before joining Roche, Jason was a consultant in the life sciences practice at L.E.K. Consulting. He also worked in finance at Amgen and in research at the University of California, San Francisco and Cytokinetics. Jason holds a Ph.D. and M.P.H. at the University of California, Berkeley, an MBA from the Tuck School of Business at Dartmouth and a B.S. in biology from the University of San Francisco.
Follow Jason Coloma:
About Maze Therapeutics: Maze Therapeutics is an operator of a biotechnology firm used to focus on translating genetic insights into new medicines.
Bret Henning
Sr Director and Information Technology of Tandem Diabetes Care
Bret Henning is currently the Sr. Director of Information Technology at Tandem Diabetes Care, Inc. Bret is responsible for worldwide IT operations including infrastructure, cloud computing, collaboration technologies, enterprise applications, DEVOPS, call center and voice technologies. At Tandem Bret was involved in building the company from an early stage startup through product commercialization. He brings a diverse portfolio of experience managing everything from Facilities to Connected Heath. His background includes more than 30 years of hands-on experience in technology for electronics and medical device companies.
Follow Bret Henning:
About Tandem Diabetes Care: Tandem Diabetes Care develops medical devices for the treatment of diabetes offering diabetic insulin pumps for adults and children.
Tad Buchanan
Director of Fabric Genomics (formerly Omicia)
Mr. Buchanan co-founded the investment firm of Buchanan Investments, Inc. in 1998 with his father, Mike. Together, they have founded, invested in and raised equity and debt capital for numerous companies, including DM&E Railroad, Central Montana Resources, Opti Canada, White Oak Resources, AlphaClone, TabletCommand, Gensys Software, Tri Alpha Energy, OneSun Solar, and numerous other private companies. Prior to founding Buchanan Investments, Inc., Tad was an Executive Director at UBS Securities with primary responsibility for managing Asian equity sales and trading based in NY. He was also an equity analyst at UBS and W.I. Carr (Far East), Ltd. based in Hong Kong, with responsibility for covering financial services, software, industrial and energy companies in Indonesia, Thailand, India, Pakistan, Sri Lanka and Bangladesh. Prior to joining W.I. Carr (Far East) Ltd., Tad was a credit analyst within the Corporate Lending Group of Wells Fargo Bank. He graduated from Pepperdine University with a B.A. in Economics and from Boston College with an M.B.A, International Finance. He currently serves on the boards of Central Montana Resources, AlphaClone, Tablet Command, and OneSun Solar. Tad is also a board observer of Tri Alpha Energy. He is married with three children, and is a Trustee of Marin Country Day School in Corte Madera, CA.
Follow Tad Buchanan:
About Fabric Genomics (formerly Omicia): Global healthcare platform for genomics-driven precision medicine. Fabric’ proven AI algorithms power genomic insights.
Jay Lichter
Managing Director of Avalon Ventures
Jay Lichter joined Avalon Ventures as Managing Director in 2007.Dr. Lichter has served on Otonomy’s board of directors since May 2008. Dr. Lichter served as the company’s chief executive officer from inception until November 2010. He is an experienced biotechnology and pharmaceutical business executive with 25 years of experience in management, scientific research and business development. Since 2007, Dr. Lichter has been a managing director at Avalon Ventures, an early stage venture capital fund focused on information technology and life sciences. In that role, he led Avalon’s investments in and served as a director and chief executive officer for privately held biotechnology companies Afraxis, Inc., Carolus Therapeutics, Inc., ReVision Therapeutics, Inc. and Zacharon Pharmaceuticals, Inc. He also currently serves on the board of directors of Aratana Therapeutics, Inc., a public company. Dr. Lichter also led Avalon’s investments in or serves on the board of privately held companies Sova Pharmaceuticals, Inc., Avelas Biosciences, Inc., COI Pharmaceuticals Inc. and Sitari Pharmaceuticals Corp. Dr. Lichter received a doctorate and bachelor’s degree in biochemistry from the University of Illinois. He also completed post-doctoral fellowships at Yale University and Du Pont Merck Pharmaceutical Company.
Follow Jay Lichter:
About Avalon Ventures, Avelas Biosciences, COI Pharmaceuticals, Fortis Therapeutics, Otonomy: Avalon Ventures is an early stage venture capital fund focused on information technology and life sciences.
Jenny Rooke
Founder & Managing Director of Genoa Ventures
Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. Jenny got her start in venture at Fidelity Biosciences, a Cambridge-based healthcare VC, during their Fund I formation. Jenny then brought her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function. In 2014, Dr. Rooke began independently investing under the brand 5 Prime Ventures, financing her investments using what has become the largest life sciences syndicate on AngelList, and one of the highest-performing AngelList syndicates of any sector. Jenny founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy, to ensure continued access to the very best deals, and to maximize portfolio returns.
Follow Jenny Rooke:
About Genoa Ventures: Genoa Ventures is a venture capital firm that invests in early-stage life sciences technology companies.
Saeid Akhtari
Managing Director of HBM Partners
Saeid Akhtari is the Managing Director at HBM Genomics investing in world-class entrepreneurs in seed and early stage startups. He has more than 20 years of experience as an entrepreneur building successful genomics companies from scratch. Saeid was the founder, President & CEO of NextBio which was acquired by Illumina in 2013. Prior to founding NextBio, he was the President & CEO of Silicon Genetics which was acquired by Agilent in 2004. Mr. Akhtari has also held executive management positions at several other life sciences companies.
Follow Saeid Akhtari:
About HBM Partners, Insitro: HBM Partners was founded in 2001 with the goal to invest in private and public emerging biopharma and other healthcare-related companies.
Jared Casner
Director, Engineering of Pear Therapeutics
Follow Jared Casner:
About Pear Therapeutics: Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Gillian Hanson
Director, Data & Informatics of PicnicHealth
Follow Gillian Hanson:
About PicnicHealth: PicnicHealth helps patients easily access their medical records and gives them the opportunity to contribute data to medical research.
Konstantin Guericke
Member of the Board of Directors of StartX (Stanford-StartX Fund)
Konstantin Guericke is a Partner at Earlybird. He is based in Silicon Valley. Konstantin is Co – Founder of LinkedIn, where he has led marketing activities from launch to first six million members and profitability as Vice President of Marketing. Previously, he has been CEO of jaxtr (social communications start-up, over ten million registered users, purchased by SabSe Technologies). Konstantin has long-time entrepreneurial experience as founder of successful startups and he has helped established companies towards increased growth. Currently, he is Board member of several startups and Mentor of student entrepreneurs at Stanford University. Konstantin holds a B.S. and M.S. in Engineering from Stanford University.
Follow Konstantin Guericke:
About : StartX is an educational non-profit that helps Stanford’s top entrepreneurs.
Dan Ha
Co-Founder, Sr. Managing Director of StartX (Stanford-StartX Fund)
Follow Dan Ha:
About StartX (Stanford-StartX Fund): StartX is an educational non-profit that helps Stanford’s top entrepreneurs.
Margi McLoughlin
Executive Director of Pfizer
Margi McLoughlin, PHD is Executive Director, WWBD and Partner at Pfizer Ventures. Margi invests in companies working in areas aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in 4D Molecular Therapeutics, Adapsyn, BioAtla, Cortexyme and System1. Through these investments, she works with the companies to help advance products and technologies of value to the pharmaceutical industry. Margi began her career at Mallinckrodt Medical, holding positions in Discovery Research, followed by Technology Planning. In 1999, she moved to Yale University where she worked as Associate Director in the Office of Cooperative Research. Since joining Pfizer Worldwide Business Development in 2001, she has had roles of increasing responsibility and led transactions with multiple biotech companies, including Ablexis, Gliknik and Excaliard. In addition, Margi played a significant role in defining Pfizer’s Centers for Therapeutic Innovation business model.
Follow Margi McLoughlin:
About Pfizer, Pfizer Venture Investments: Pfizer provides access to safe and effective and affordable medicines and health care services.
Colton Pierson
Director Of Engineering of Curative
Follow Colton Pierson:
About Curative: Curative is a leader in on-demand public health programs and infrastructure. We’re building a healthier tomorrow, together.
Samara Freeman
Director, IP & Regulatory Affairs of Evolve Biosystems
Samara was one of the co-founders of Evolve Biosystems. Samara has qualifications in both science and management and has worked in research management and biotech in the US and internationally. Samara has co-authored numerous scientific articles and is an invited and keynote speaker at milk and dairy conferences.
Follow Samara Freeman:
About Evolve Biosystems, Evolve Biosystems: Evolve Biosystems specializes in providing microbiome-based products designed to develop, restore, and maintain.
Charles P. McKenney
Board of Directors of Arrowhead Pharmaceuticals
Charles P. McKenney has maintained a government affairs law practice in Pasadena, California since 1989, representing businesses and organizations in their relations with government regarding their obligations under state and local land use and trade practices laws. From 1973 through 1989, he served as Attorney for Corporate Government Affairs for Sears, Roebuck and Co., helping organize and carry out Sears’ Western state and local government relations programs. Mr. McKenney has served two terms on the Pasadena, California City council, on several city boards and committees in Pasadena, including three city Charter Reform Task Forces.
Follow Charles P. McKenney:
About : Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Edward W. Frykman
Board of Directors of Arrowhead Pharmaceuticals
Edward W. Frykman has been an Account Executive with Crowell, Weedon & Co. since 1992. Previously, Mr. Frykman served as Senior Vice President of L.H. Friend & Co. Both Crowell, Weedon & Co. and L.H. Friend & Co. are investment brokerage firms located in Southern California. In addition, Mr. Frykman was a Senior Account Executive with Shearson Lehman Hutton where he served as the Manager of the Los Angeles Regional Retail Office of E. F. Hutton & Co.
Follow Edward W. Frykman:
About : Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Alain Azan
President and Managing Director Emeritus of Sofinnova Investments
Alain Azan is the Founding Partner of Sofinnova Ventures. He joined Sofinnova SA in France in 1983 and relaunched Sofinnova Inc. in San Francisco in 1987. During his 25 years as a venture capitalist, Alain has made over 50 investments in the information technology sector, resulting in over 25 IPOs and trade sales. Most notable are his investments in Phone.com (Nasdaq: OPWV), Premisys (acquired by Zhone Technologies), Tumbleweed (Nasdaq: TMWD), Element 14 (acquired by Broadcom), Ray Dream (acquired by Fractal Design), and DataMind (acquired by Epiphany). Prior to beginning his career in venture capital, Alain was an executive in the oil and gas exploration and machine tool industries, where he held a variety of operational roles based out of several countries. He has also received the national honor of “Chevalier de la Legion d’Honneur” in 2006, as published in France’s Journal Officiel de la Republique Francaise. Alain studied Mechanical Engineering and Economics at the Marseilles-Luminy University in France, and received an M.B.A. from the INSEAD (Fontainebleau, France).
Follow Alain Azan:
About Sofinnova Investments: Sofinnova Investments specializes in seed, startup, mid, early stage, series A, first venture round, and corporate spinouts.
Benjamin Cravatt
Director and Co-Founder of Boundless Bio
Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. Ben obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.
Follow Benjamin Cravatt:
About Boundless Bio, Vividion Therapeutics: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Aenor Sawyer
Director, University of California, Space Health; Dir. Skeletal Health Service of University of California, San Francisco
Aenor Sawyer is an Orthopaedic Surgeon at UCSF and Associate Director of Digital Health in Biomedical Informatics at the Clinical & Translational Science Institute where she co-directs the UCSF T1 Catalyst Digital Health Grants program. Aenor Sawyer is also co-Founder of Trinity, a web-based collaboration technology for Virtual Tumor Board and Multidisciplinary Management of complex patients.
Follow Aenor Sawyer:
About Translational Research Institute for Space Health (TRISH), Trinity Labs, University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Sanchita Bhattacharya
Scientific Program Director of University of California, San Francisco
Sanchita Bhattacharya is the Bioinformatics Project Lead at UCSF School of Medicine.
Follow Sanchita Bhattacharya:
About UCSF School of Medicine, University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Daniel Lowenstein
Director, Physician-Scientist Education & Training of University of California, San Francisco
Daniel Lowenstein is the Director, Physician-Scientist Education & Training at UCSF.
Follow Daniel Lowenstein:
About University of California, San Francisco, University of California, San Francisco, University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Gregory Grunberg
Managing Director of Longitude Capital
Dr. Gregory Grunberg joined Longitude Capital in 2012 as a Managing Director. He focuses on investments in medical devices and biotechnology. Prior to joining Longitude, Dr. Grunberg was a Principal at Rho Ventures, a multi-stage, multi-sector fund, where he participated in medical device, biotechnology and other healthcare investments. Before joining Rho, Dr. Grunberg was an Engagement Manager in the life sciences practice of McKinsey & Company. While at McKinsey, he worked with many large life sciences companies and private equity investors across a range of projects encompassing investment due diligence, business development, R&D, and product development. He also consulted at The Parthenon Group and led his own health care advisory firm during graduate school. Greg is a board-certified physician in Internal Medicine and completed his residency at Weill-Cornell’s New York Presbyterian Hospital. He has maintained a limited clinical practice in Internal Medicine and affiliations with UCSF, Kaiser, Albert Einstein, U. Miami, Weill-Cornell, and the Weill-Cornell Buganda Medical School in Tanzania.
Follow Gregory Grunberg:
About Kaiser Permanente, Longitude Capital, UCSF health: Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.
Patrick Enright
Founder and Managing Director of Longitude Capital
Patrick Enright is the Board Member at Esperion Therapeutics.He has served as a Member Of Board Of Directors since April 2013.He is also the Managing Director, Longitude Capital Management Co., LLC. Patrick is a founder of Longitude Capital Management Co., LLC, a venture capital firm focused on investments in biotechnology, and has served as its Managing Director since 2007. From 2002 through 2006, Patrick was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, Patrick was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately held and publicly traded biotechnology companies. Patrick is a director of a number of companies including,Corcept Therapeutics, Inc. (NASDAQ: CORT),Jazz Pharmaceuticals plc (NASDAQ: JAZZ).Patrick earned an M.B.A. from the Wharton School of Business at the University of Pennsylvania.B.S. in Biological Sciences from Stanford University.
Follow Patrick Enright:
About Longitude Capital: Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.
Marc Galletti
Managing Director of Longitude Capital
Mr. Galletti is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Galletti was a Senior Vice President of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot Ventures, Mr. Galletti worked at Amerindo Investment Advisors, Vector Fund Management and the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his career in the life sciences industry at APM, a management consultancy dedicated to improving operations performance within the patient care and procedural units of large acute-care hospitals. Mr. Galletti currently serves on the boards of Amphora Medical and Murj. He has previously served on the boards of Aptus Endosystems (acquired by Medtronic) and Twelve (acquired by Medtronic) and has also been involved with prior investments in Ablation Frontiers (acquired by Medtronic), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Ovation), Sadra Medical (acquired by Boston Scientific), and Threshold Pharmaceuticals (THLD). Mr. Galletti sits or has sat on advisory boards for the Innovation and New Ventures Office at Northwestern University, the Program for Biomedical Engineering at Brown University, the Venture Capital Advisory Board of AdvaMed and the Life Sciences Advisory Board of Silicon Valley Bank. Mr. Galletti holds an M.B.A. in Finance and Health Services Management from the Kellogg School of Management at Northwestern University and an A.B. from Princeton University.
Follow Marc Galletti:
About Longitude Capital: Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.
Ivan Lai
Senior Director, Global Supply Chain of Stryker
Follow Ivan Lai:
About Dexcom, Koderon, Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Mark Mastandrea
Senior Director, Supply Chain of Stryker
Follow Mark Mastandrea:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Irene Choi
Director, Drug Discovery of Verge Genomics
Irene has nine years of experience leading multiple neuroscience drug discovery programs from idea to clinic. Prior to Verge, she led early discovery, pharmacology, and program teams at Nektar Therapeutics. There, she helped bring several drugs to clinic, including NKTR-181, a first-in-class mu-opioid analgesic currently in Phase 3 clinical trials. Irene completed her post-doctoral training in Catherine Rivier’s group at the Salk Institute for Biological Studies and received her Ph.D. in Neurosciences from the University of New Mexico.
Follow Irene Choi:
About Verge Genomics: Verge Genomics uses machine learning and human genomics to accelerate drug discovery.
Udi Lazimy
Plant Sourcing Director of Eat Just
Follow Udi Lazimy:
About Eat Just: Eat Just offers a plant-based egg substitute intended to provide healthy and nutritional food alternatives.
Daniel Scharff
Director of Strategy & Analytics of Eat Just
Daniel Scharff is the director of Strategy & Analytics for JUST, Silicon Valley-based company on a mission to build a food system where everyone eats well. In this capacity, Scharff is focused on global consumer insights, product pricing, and revenue strategy. Prior to JUST, Scharff worked as a strategy consultant with Deloitte, and a global pricing executive for Mars Chocolate. He holds an MBA from The Wharton School, an MA in International Studies from The Lauder Institute (UPenn), and a B.A. in Psychology from Kenyon College.
Follow Daniel Scharff:
About Eat Just: Eat Just offers a plant-based egg substitute intended to provide healthy and nutritional food alternatives.
Vítor Espírito Santo
Director, Cellular Agriculture of Eat Just
Vitor is the Director of Cellular Agriculture at JUST, leading a biotechnology and cell culture program towards the development of cultured meat. His main focus is to select animals and breeds of interest and strategically isolate, identify and characterize novel cell candidates amenable for manufacturing. The main mission of JUST is to produce cultured meat that is affordable, delicious and available to everyone while simultaneously overcoming food safety, environmental and ethical hurdles that they’re facing nowadays with conventional meat productio
Follow Vítor Espírito Santo:
About Eat Just: Eat Just offers a plant-based egg substitute intended to provide healthy and nutritional food alternatives.
Chris Jones
Director of Culinary Innovation of Eat Just
Follow Chris Jones:
About Eat Just: Eat Just offers a plant-based egg substitute intended to provide healthy and nutritional food alternatives.
Jessica Elkus
Director of Communications of Eat Just
Follow Jessica Elkus:
About Eat Just: Eat Just offers a plant-based egg substitute intended to provide healthy and nutritional food alternatives.
Dave Schulte
SVP, Managing Director of McKesson Ventures
Dave has more than 15 years of experience, as an investor and investment banker, partnering with entrepreneurs to build innovative health care and technology businesses. He joined Kasier Permanente Ventures in 2003 and helped build KP’s investment program. He is now responsible for managing the Fund’s investment strategy and day to day activities. Prior to KP Ventures, Dave was a health care and software investment banker at J.P. Morgan, UBS, and Piper Jaffray. He serves or served as a Board Director or Observer for several companies: Atheromed, Baxano (sold to Trans1), Hemosphere (sold to Cryolife) , MetricStream, Nursefinders (sold to Goldman Sachs), Proteus Biomedical, Pulmonx, ValenTx, Valeritas and Xanitos. Dave is a graduate of St. John’s University and earned a Master of Public Policy degree from Harvard University.
Follow Dave Schulte:
About McKesson Ventures: McKesson Ventures is a California-based venture capital that focuses on the healthcare industry.
Paul F. Truex
President & CEO, Director of Anthera Pharmaceuticals
Mr. Truex has served as Director, President and Chief Executive Officer since the inception of Anthera in 2004.He was responsible for negotiating Anthera’s product license for A-623, our anti-BAFF peptibody program from Amgen.Prior to founding Anthera Pharmaceuticals, Mr. Truex served as a Founder, Director, President and CEO of Peninsula Pharmaceuticals.During that time Mr. Truex raised over $81 million of institutional capital (including $21 million from a strategic partner) and negotiated both of Peninsula’s product agreements with Shionogi & Co., Ltd. (Doribax®, doripenem) and Takeda Chemical Industries (Teflaro®, ceftaroline). Peninsula was acquired by Johnson and Johnson in April of 2005 for $245 million in an all cash transaction.The remaining entity, Cerexa was subsequently acquired in 2006 for $480 million in cash.During his career, Mr. Truex has successfully raised over $150 million in venture investments and more than $500 million in various public and private equity and debt offerings including Anthera’s Initial Public Offering in 2010 and Versicor’s IPO in 2000.Mr. Truex has extensive experience in sales’ marketing and business development in several industries including pharmaceuticals, biotechnology, consumer electronics, and telecommunications.Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Versicor Incorporated (acquired by Pfizer) where he directed early commercial efforts for their infectious disease portfolio and participated in the company’s successful $55 million initial public offering.Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos®’ Evista®’ and Humalog 75/25®). His business development experience includes the Lilly ICOS LLC joint venture’ two majorproduct divestitures and numerous small research collaborations. While there Mr. Truex also worked with several product teams on various divestiture strategies.Mr. Truex obtained his Masters of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo.Mr. Truex is a member of the Board of Directors of Trius Therapeutics, Milestone Pharmaceuticals and Waterloo Pharmaceuticals, Inc.
Follow Paul F. Truex:
About Anthera Pharmaceuticals: Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.
David Cory
President and Chief Executive Officer, Board Director of Eiger BioPharmaceuticals
David Cory is an entrepreneur and industry veteran with 25-years experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational, transactional, and financial success.Mr. Cory is currently the President and CEO of Eiger BioPharmaceuticals since 2008. He is responsible for negotiating Eiger’s multiple product licenses from Merck and Astra Zeneca. Cory was previously President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail Pharmaceuticals for $160 million in 2008. Cory was Co-Founder and Chief Commercial Officer at CoTherix, an Orphan Pulmonary Hypertension company, which was acquired by Actelion for $425 million in 2006. Cory began his start up career as Senior Vice President of Commercial Operations at InterMune, a public biotechnology company focused on developing Orphan products for Idiopathic Pulmonary Fibrosis. He was as a key executive in the InterMune IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. Mr. Cory spent the first 12 years of his career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline leading teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, where he directed 10 pharmaceutical product launches and the commercialization of 20 brands.David Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masters Degree in Business Administration from the University of Maryland.
Follow David Cory:
About Eiger BioPharmaceuticals: Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
Nicholas J. Simon
Managing Director of The Blackstone Group Inc
Nicholas Simon has been a Managing Director of Clarus since the firm’s inception in 2005. Prior to Clarus, Nicholas Simon was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 20 years of operating and investment experience in the biopharmaceutical industry including Genentech from 1989 to 2000 where he was Vice President of Business and Corporate Development. Nicholas Simon received a BS degree in microbiology from the University of Maryland and an MBA from Loyola University. Nicholas Simon is a Trustee at The J David Gladstone Institutes, a private not-for-profit research institute affiliated with the University of California, San Francisco.
Follow Nicholas J. Simon:
About Blackstone Life Sciences, ITM Solutions, The Blackstone Group Inc: Clarus Ventures is a Massachusetts-based venture capital firm focused on investments in the healthcare sector.
Miyoko Sakashita
Oceans Director, Senior Attorney of Center for Biological Diversity
Miyoko Sakashita, Oceans Director, Senior Attorney, works with the oceans team to secure protections for imperiled marine life and ecosystems from threats ranging from global warming and ocean acidification to fisheries and pollution. Miyoko holds a law degree from the University of California at Berkeley, where she also earned a bachelor of science degree in conservation and resource studies. Prior to joining the Center, Miyoko was a local currency activist and sustainable agriculture advocate.
Follow Miyoko Sakashita:
About Center for Biological Diversity: At the Center for Biological Diversity, we believe that the welfare of human beings is deeply linked to nature
Peter Galvin
Co-Founder, Director of Programs of Center for Biological Diversity
Peter Galvin, Director of Programs, is a founder of the Center. He holds a bachelor’s from Prescott College and a master’s degree from Norwich University. Peter helps coordinate the Center’s legal actions and campaigns, assists in the formulation of organizational policy and strategy and serves on the Center’s leadership team. Before working for the Center, he worked as a contract wildlife researcher for the U.S. Forest Service, U.S. Fish and Wildlife Service and Arizona Game and Fish Department. A longtime environmental activist, Peter also serves on the board of directors of the Beech Hill Foundation and is a member of the Science Oversight Team for the Global Owl Project.
Follow Peter Galvin:
About Center for Biological Diversity: At the Center for Biological Diversity, we believe that the welfare of human beings is deeply linked to nature
Geoffrey Parker
Board of Directors of ChemoCentryx
Geoffrey M. Parker has served as our Senior Vice President and Chief Financial Officer since September 2010, after serving in a consulting capacity since December 2009. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, a privately held biopharmaceutical company in Los Altos, California. From 1997 to April 2009, Mr. Parker was a Vice President, then Managing Director and finally Partner at the global investment banking and securities firm Goldman Sachs Group, Inc., leading their West Coast Healthcare Investment Banking practice during this time. Mr. Parker also served in various capacities with Goldman Sachs Group, Inc. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker is currently a member of the board of directors of Genoptix, Inc., a specialized laboratory service provider and ChemoCentryx, Inc., a clinical stage privately held biopharmaceutical company. Mr. Parker received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from Stanford University.
Follow Geoffrey Parker:
About Tricida: ChemoCentryx develops orally administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Ed Klosterman
Director, US Field Service Operations of bioMerieux
Ed Klosterman is the Director of U.S. Field Service Operations for bioMérieux, a leading medical diagnostic company. With his undergrad in engineering / business, he completed his MBA at Webster University. Ed is a standout leader that has directed high performing teams built for achievement and agility, while guiding an industry recognized customer support operation. With greater than 20 years of experience in the global medical diagnostic service industry, Ed is passionate about his work and contribution toward improve healthcare in America. On a personal level, Ed sits on the board for the Boys & Girls Club and active within his community speaking at high schools about many topics, including careers in healthcare.
Follow Ed Klosterman:
About bioMerieux: bioMérieux develops and produces in vitro diagnostic solutions for private and hospital laboratories, mainly for the diagnosis.
Li Weng
Director of AccuraGen Holdings
Li currently leads AccuraGen’s R&D. With her extensive knowledge and industry experience in genomic technology, she has spearheaded the development of a next generation sequencing (NGS)-based ctDNA assay suite which includes an amplicon-based NGS technology for SNV and fusion detection. Li is responsible for translating new technology developments into clinical actionables (LDT and potential IVD kit) for AccuraGen’s clinical labs in China as well as for GMP production. Li received her PhD in cancer biology from the University of Chicago and completed her postdoctoral studies at the Lawrence Berkeley National Laboratory where she worked on a sequencing-based assessment of human disease. She then moved to Affymetrix and later to Sequenta, where she managed the development and FDA-approval process of the company’s flagship product, a NGS-based technology for immuno profiling and MRD detection in patients with lymphoid cancer.
Follow Li Weng:
About AccuraGen Holdings: A cancer early detection company
Karl Kerksiek
Investment Director of Finistere Ventures
Karl Kerksiek is an Associate in Finistere’s Silicon Valley office where he leads the firm’s focus on agricultural applications of new finance and supply chain technologies. His investment interests include new technologies in lending, credit evaluation, derivatives, insurance, trading, online markets, crowd-sourcing, traceability, and blockchain. Prior to Finistere, Karl was a Principal at the Mitchell Madison Group where he led teams in the US and Asia. He brings a decade of management consulting experience using data science to advise C-suite executives on strategic and operational challenges in consumer & enterprise software, financial services, healthcare, manufacturing, and information technology. Karl has an MA from Stanford University, where his graduate work focused on the implication of China’s non-performing debt problem for future economic growth. Karl is fluent in Mandarin and has a BA from Pomona College.
Follow Karl Kerksiek:
About Farmer’s Fridge, Finistere Ventures, Good Eggs, Innit, Plenty, Taranis, Tovala: Finistere Ventures is a venture capital firm that seeks investments in the agriculture sector.
Spike Loy
Managing Director of Biotechnology Value Fund
Follow Spike Loy:
About Biotechnology Value Fund: Biotechnology Value Fund, L.P. is an evergreen fund specializing in early stage financing. It focuses on undervalued investment
David-Alexandre Gros
Co-Founder, Director and Chief Executive Officer of Imbria Pharmaceuticals
David-Alexandre is the co-founder, director and chief executive officer at Imbria Pharmaceuticals.
Follow David-Alexandre Gros:
About Imbria Pharmaceuticals: Imbria Pharmaceuticals is a biotechnology company with locations in San Diego, CA, and Boston, MA.
Joshua Kazam
Co-Founder and Director of Kronos Bio
Joshua is the Co-Founder and Director of Kronos Bio. Mr. Kazam is a co-founder and Partner of Two River. He also serves as an Officer and Director of Riverbank Capital Securities, Inc., a FINRA member broker-dealer (“Riverbank”). Prior to co-founding Two River, he was employed by a venture capital firm specializing in biotechnology investments, where he most recently served as Managing Director and was responsible for ongoing operations of venture investments. In addition, Mr. Kazam served as the Director of Investment Management for the Orion Biomedical Fund, a New York-based private equity fund focused on biotechnology investments. Mr. Kazam is a co-founder and director of Kite Pharma (KITE) and serves on the Board Capricor Therapeutics (CAPR). In addition, Mr. Kazam also currently serves as a director of several privately held companies including Vetprime, Inc. Mr. Kazam received his degree in entrepreneurial management from the Wharton School of the University of Pennsylvania and resides in New York City.
Follow Joshua Kazam:
About Allogene Therapeutics, Kite Pharma, Kronos Bio, Two River: Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer.
Ann F. Hanham
Managing Director of Burrill & Company
Ann F. Hanham joined Burrill & Company in February, 2000, and has utilized her background in clinical and regulatory affairs to lead deals in diagnostic, device and therapeutic opportunities. Prior to joining Burrill & Company, Ann was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune Pharmaceuticals, and prior to that, the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and the Medical Director for Celtrix Pharmaceuticals. She has also worked for Becton Dickinson in both regulatory and clinical affairs in their monoclonal antibody program, and as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. Dr. Hanham holds a Ph.D. from the University of British Columbia, an M.Sc. from Simon Fraser University, and a B.Sc. from the University of Toronto. She was also Board Certified in Toxicology in 1986. She is currently the CEO of Adlyfe, and a member of the Board of Directors of Adlyfe, Endocyte, SCYNEXIS, and Waterstone. Ann is also a charter member of the C100, a group dedicated to assisting Canadian entrepreneurs.
Follow Ann F. Hanham:
About Burrill & Company: Burrill & Company is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies.
Tao Fu
President, COO & Director of Zai Lab
Tao Fu has been our President & Chief Operating Officer since September 2018. Prior to joining Zai Lab, he worked with Portola Pharmaceuticals, where he served as Executive Vice President, Chief Commercial and Business Officer, responsible for commercial operations, marketing, sales and business development functions. Prior to joining Portola in June 2015, Tao was Vice President and Head of Mergers & Acquisitions and Alliance Management at Bristol-Myers Squibb (BMS). At BMS, he was responsible for the company’s corporate development, alliance management and venture activities. Between 2003 and 2014, he held several leadership positions with increasing responsibilities at Janssen, the pharmaceuticals group of Johnson & Johnson, most recently as Vice President, Business Development, where he led global M&A activities. He also has experience in business development, commercial strategy and management consulting with McKinsey & Company, Becton Dickinson, etc. Tao holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University in Beijing, China and is a Chartered Financial Analyst (CFA).
Follow Tao Fu:
About Zai Lab: Zai Lab brings transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world.
Arthur Keledjian
Member of the Board of Directors of VG Life Sciences
Arthur Keledjian has served as a member of our Board of Directors since 2001. Arthur Keledjian has been involved with us since our inception and is a valuable addition to our Board of Directors due to his longevity with us and extensive strategic advising experience. Arthur Keledjian is responsible for procuring and managing over $10 million in annual sales with SCI – Hispana in his business development role. He is based in Los Angeles, CA. Arthur Keledjian graduated from California State University, Los Angeles with a Bachelor of Science in Business Administration & Marketing.
Follow Arthur Keledjian:
About : VG Life Sciences discovers and develops drug therapies for cancers, infectious diseases, inflammatory diseases, and autoimmune disorders.
Greg Jagiello
Director, Product Design of Vineti
Software product person with deep user experience and product design roots. Some of the personal attributes that I bring to the table: – A bias toward action – Able to make decisions with imperfect information – Passion for creating simple and compelling user experiences – Solid design and user experience instincts – Entrepreneurial “get it done” attitude – A player who wants to work with A+ players – Accomplish a lot quickly with limited resources – A force multiplier in startups I use a metrics-informed and user-researched approach, focusing on adoption of nascent web and mobile products. I’m particularly interested in emerging technologies (drones/UAVs, health and fitness devices, virtual 3d reality, mobile payments).
Follow Greg Jagiello:
About Vineti: Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
Nicholas Moore
Independent Director of Gilead Sciences
Nicholas G. Moore joined Gilead’s Board of Directors in March 2004. Moore is the retired global Chairman of PricewaterhouseCoopers LLP, a professional services firm formed in July 1998 by the merger of Coopers & Lybrand and Price Waterhouse. Prior to the merger, Moore was elected Chairman and Chief Executive Officer of Coopers & Lybrand (U.S.) in 1994 and Coopers & Lybrand International in 1997. Moore is the lead independent director of NetApp and a director of Bechtel Group, Inc., Wells Fargo, N.A. and E2 Open. He has also served as Chairman of the Board of Trustees of St. Mary’s College of California. Moore is an inactive member of the American Institute of Certified Public Accountants, the California Bar Association, and the California and New York Society of Certified Public Accountants.
Follow Nicholas Moore:
About AICPA, California Society of Certified Public Accountants, Gilead Sciences: Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Teresa Wang
Director, Investor Relations of Gilead Sciences
Follow Teresa Wang:
About Gilead Sciences: Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Brian Peters
Senior Director, Procurement of Gilead Sciences
Brian Peters is the senior director of procurement at Gilead Sciences.
Follow Brian Peters:
About Gilead Sciences: Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Joel Bercu
Sr Director of Gilead Sciences
Follow Joel Bercu:
About Gilead Sciences, Gilead Sciences, Gilead Sciences: Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Todd Reul
Director, Clinical Outsourcing of Global Blood Therapeutics
Follow Todd Reul:
About Global Blood Therapeutics: GBT is a clinical-stage biopharmaceutical company developing its lead product candidate, voxelotor, as a therapy for sickle cell disease.
Slawek Wojtowicz
Senior Medical Director of Quintiles
Follow Slawek Wojtowicz:
About Quintiles, Stanford University: Quintiles is a provider of biopharmaceutical development and commercial outsourcing services for drugs on the market.
Kevin Appelbaum
Co-founder, CEO & Board Director of Better Therapeutics
Member of American College of Lifestyle Medicine & Co-founder, CEO & Board Director of Better Therapeutics.
Follow Kevin Appelbaum:
About Better Therapeutics, Confidential Digital Health Startup (funded): Better develops prescription software for treating cardiometabolic diseases.
Brian Armbrust
Senior Director, People & Culture | Global Business Partner, Pharma Product Development of Genentech
Brian Armbrust is a Principal Human Resources Business Partner at Genentech in South San Francisco, CA. Genentech, a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. Genentech became an affiliate of the Roche Group (Basel, Switzerland) in 2009. He is a people strategy leader in Global Product Development Biometrics. Biometrics sets the analytic strategy and delivers quantitative evidence for Genentech/Roche’s robust product portfolio (early phase through post-marketing) and is based in six sites in Europe, North America and Asia. The 900-person function is comprised of statisticians, real world data scientists, outcomes research scientists and other data analysis/management professions. Prior to joining Global Product Development, Brian was an HR business partner in for Genentech/Roche Product Technical Operations, providing strategic HR consultation to leaders of a 1200 employee biologics production facility. From 2003-2011, he held a variety of HR roles (operations, training, change management and business partner) at McKesson in San Francisco. His clients at McKesson included leaders in product management, finance, marketing, and sales support. Brian previously worked in marketing communications and began his career as a high school English and journalism teacher. Brian’s clients recognize him for having an innovative style and for successfully aligning a wide variety of business goals to talent initiatives and programs. Some of his areas of expertise include: leadership development, organizational effectiveness, talent management, change leadership and employee engagement. He holds a BA (English, communication studies) from the University of Michigan, Ann Arbor; and an MBA (general management, strategy) from the Haas School of Business, University of California, Berkeley.
Follow Brian Armbrust:
About Genentech: Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients.
Bob Cook
Director of Real Estate Assets of Genentech
Director of Real Estate Assets at Genentech.
Follow Bob Cook:
About : Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients.
Jeb Taylor
Associate Director of Genentech
Follow Jeb Taylor:
About Genentech: Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients.
Quita Highsmith
Franchise Head, Senior Director of Tamiflu of Genentech
Quita Highsmith is the Franchise Head and Senior Director for Tamiflu at Genentech. She leads and oversees the commercial strategy and is responsible for the overall profit and loss of her organisation. She manages the only brand at Genentech that runs a direct to consumer television, print and online campaign. In her previous role as National Sales Director for Rheumatology, she led the largest Genentech field force at the time. Prior to joining Genentech, she was with Sanofi. There she held numerous roles of increasing responsibility including Director – US Advocacy, Senior Marketing Manager, Regional Sales Director and Hospital Division Manager. While in marketing, she won the 2009 Top 25 DTC Marketer of the Year from DTC Perspectives Magazine. She started in the industry at Rhone-Poulenc Rorer in 1991 as a sales representative. While in sales, Quita worked in numerous markets across the US and won awards on every level. Quita received her MBA from Cornell and her undergraduate degree from the University of Kentucky. In her spare time, Quita is passionate about mentoring and community service.
Follow Quita Highsmith:
About : Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients.
Dot Reilly
Associate Director of Genentech
Associate Director at Genentech.
Follow Dot Reilly:
About Genentech: Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients.
Firehiwot Tachea
Director of Fermentation of Culture Biosciences
Firehiwot Tachea is the Director of Fermentation at Culture Biosciences.
Follow Firehiwot Tachea:
About Culture Biosciences: Culture Biosciences develops automated bio-reactors that help companies optimize their manufacturing processes.
Rick Devenuti
Director & Member, Audit Committee of St. Jude Medical
Rick Devenuti is President of the Information Intelligence Group (IIG), a division of EMC Corporation. With revenues of $21.7 billion in 2012 and 60,000 people worldwide, EMC is a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service. Fundamental to this transformation is cloud computing. Through innovative products and services, EMC accelerates the journey to cloud computing, helping IT departments to store, manage, protect and analyze their most valuable asset—information—in a more agile, trusted and cost-efficient way. Devenuti was appointed to his current position in October 2010. In his role, Devenuti oversees all aspects of IIG’s business including worldwide sales and services, channel strategy, product development, marketing, strategic business and financial initiatives, IT, technical support and the Total Customer Experience program. He previously served as the division’s chief operating officer. He joined EMC following a successful 19-year career at Microsoft Corporation. Most recently, he served as Senior Vice President of Microsoft Services and IT responsible for strategy and operational performance of Microsoft Enterprise Services, Customer Service and Support, Software-as-a-Service business and IT. In that role, he significantly expanded the Enterprise Services business, introduced support offerings resulting in improved customer satisfaction and launched Microsoft Managed Services, the company’s first software-as-a-service offering for enterprise customers. Devenuti joined Microsoft in 1987 and focused his career on creating and managing operational excellence. As chief information officer, he established metrics to measure IT value at Microsoft and integrated business processes and business acumen into IT, resulting in efficiency gains for end users and cost savings for the company. Before becoming CIO, Devenuti was vice president of worldwide operations where he directed all activities related to Microsoft product information and release management, manufacturing, distribution, and transaction processing. He also held numerous operational positions at Microsoft including general manager of North American operations, general manager of U.S. sales operations, director of financial analysis, controller and cost accounting manager. Prior to Microsoft, he spent four years at Deloitte Touche as a Senior Accountant. Devenuti earned his Bachelor of Science Degree in Accounting from University of Washington. He currently serves on the Boards Of Directors for St. Jude Medical and Convergys Corporation.
Follow Rick Devenuti:
About Dell EMC: St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac,
Naj Sharif
Executive Director, and Head Global Biomedical Sciences/ Alliances & External Research of Santen Pharmaceutical
Follow Naj Sharif:
About Santen Pharmaceutical: Santen is a Japanese pharmaceutical company specializing in the development and manufacturing of ophthalmic products.
Sundeep Dugar
Founder & Director of Sphaera Pharma
Sundeep Dugar is the Director at Epirium Bio. He is also the Founder of Sphaera Pharma.
Follow Sundeep Dugar:
About Epirium, Sphaera Pharma: Sphaera Pharma is engaged in the discovery and development of pharmaceutical drugs.
Cindy Tahl
Senior Director of Intellectual Property and Corporate Counsel of Fate Therapeutics
Follow Cindy Tahl:
About Fate Therapeutics, Fate Therapeutics, Fate Therapeutics: Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Rob Hopfner
Managing Director of Bay City Capital
Rob Hopfner, BSP, PhD, MBA, is an Investment Partner at Bay City Capital and has been with the firm since August 2002. Rob Hopfner focuses on biopharmaceutical investments and his investments include Dermira, Inc., Hyperion Therapeutics, Inc., NextWave Therapeutics, Inc., Tetraphase Pharmaceuticals, Inc., and Tria Beauty, Inc. Before joining Bay City Capital, Rob Hopfner worked in DuPont Pharmaceuticals’ Business Development & Strategic Planning group and at Ag-West Biotech, a Western Canadian seed-stage biotech venture capital firm.Rob Hopfner holds a PhD in Pharmacology and a BS in Pharmacy from the University of Saskatchewan and an MBA from the University of Chicago Booth School of Business. His biomedical research was focused on endocrine pharmacology and he completed post-doctoral work at Harvard Medical School. Rob Hopfner won numerous awards during his research career, including the Governor General of Canada Gold Medal Award in 2000, and published several articles in top medical journals based on his work. Rob Hopfner started his career as a pharmacist.
Follow Rob Hopfner:
About Bay City Capital: Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Fred Craves
Managing Director of Bay City Capital
Fred Craves, PhD, is an Investment Partner, Managing Director and Founder of Bay City Capital, and serves as a member of the board of directors and Chairman of the executive committee. Before founding Bay City Capital, he spent over 20 years leading and managing biotechnology and pharmaceutical companies. Previously, he was Executive Vice President of Schering Berlin and Chief Executive Officer and President of Berlex Biosciences, a research, development, and manufacturing organization. He founded Burrill & Craves, a merchant bank focused on biotechnology and emerging pharmaceutical companies. He was also the founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules. Dr. Craves is a member of the boards of directors of Poniard Pharmaceuticals, Dermira, Madrigal Pharmaceuticals and Reset Therapeutics. He also serves as a member of The J. David Gladstone Institutes’ Advisory Council and is a member of the Board of Trustees of Loyola Marymount University in Los Angeles. Dr. Craves earned a BS in Biology from Georgetown University and a PhD in Pharmacology and Toxicology from the University of California, San Francisco.
Follow Fred Craves:
About Bay City Capital: Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Judy Koh
Managing Director/Chief Financial Officer of Bay City Capital
Judy Koh, MBA, CPA, is an Operating Partner and the Chief Financial Officer at Bay City Capital and has been with the firm since April 1998.
Follow Judy Koh:
About Bay City Capital, Illumina Ventures: Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
David Beier
Managing Director of Bay City Capital
David Beier, JD is a Managing Director with Bay City Capital, and has been with the firm since 2013. David served as a senior officer for nearly a decade in each of the two largest biotechnology firms, Genentech and Amgen. Most recently, David Beier was a member of the senior management team at Amgen. As Senior Vice President, he had responsibility for global government affairs, as well as corporate communications, and philanthropy. During his Amgen tenure he also helped create and supervised the firm’s coverage, reimbursement, access, pricing, and healthcare economics activities globally. Earlier in his career, he was Chief Domestic Policy Advisor to the Vice President in the Clinton Administration. David Beier has been a partner in a large international law firm as well as Counsel to the US House of Representatives Committee on the Judiciary. He is admitted to practice law in New York and the District of Columbia.
Follow David Beier:
About Bay City Capital: Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Jack Zhang
CEO,CSO, and Director of Amphastar Pharmaceuticals
Jack Y. Zhang, Ph.D. has served as Amphastar Pharmaceutical’s Chief Executive Officer and as a member of the Board of Directors since its inception in 1996. He has also served as Amphastar’s Chief Science Officer since 2005 and as the President from 1996 until June 2013. Dr. Zhang has over 35 years of experience in chemistry, physics, management, and training including operations management of a chemical manufacturing facility with more than 2,000 employees to the start-up of an analytical laboratory serving defense cleanup. He is the co-founder of Applied Physics & Chemistry Laboratory (“APCL”), a full service, chemical analytical laboratory in Chino, California, where he held the position of President for 15 years. Dr. Zhang is named as the inventor on several U.S. and foreign patents and has authored numerous academic publications. He received a Ph.D. in Chemistry from the State University of New York at Stony Brook and was a Post Doctoral Research Associate at the California Institute of Technology.
Follow Jack Zhang:
About Amphastar Pharmaceuticals: Amphastar Pharmaceuticals specialty pharmaceutical company that is engaged in the development, manufacture and marketing of generic.
Robert Clark
Director of Cheminformatics of Simulations Plus
Bob Clark joined Simulations Plus as Sr. Research Fellow in 2010.
Follow Robert Clark:
About Indiana University, Simulations Plus: Simulations Plus is a developer of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET).
Robert Clark
Director of Cheminformatics of Simulations Plus
Bob Clark joined Simulations Plus as Sr. Research Fellow in 2010.
Follow Robert Clark:
About Indiana University, Simulations Plus: Simulations Plus is a developer of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET).
William Biggs
Sr. Director & Site Head of Guardant Health
Follow William Biggs:
About Guardant Health: Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs in oncology.
Allison Duettmann
President & Executive Director of Foresight Institute
Allison conducts research and coordinates the technical programs. Her research focus is on the reduction of existential risks, especially from Artificial General Intelligence. At Existentialhope.com she keeps an index of readings, podcasts, organizations, and people that inspire an optimistic long-term vision for humanity. The index is collaborative and for everyone who wants to improve the world but doesn’t know where to start. Allison speaks and moderates panels on existential risks & existential hope, AI safety, longevity, blockchains, ethics in technology, and more. Prior to Foresight she hosted and planned TEDx, panels, workshops, debates, and conferences for governments, companies, think tanks, NGOs and the public in Germany, France, Colombia, the UK, and the US. Allison holds a Summa Cum Laude MS in Philosophy & Public Policy from the London School of Economics, where she developed a moral framework for Artificial General Intelligence that relies on natural language processing.
Follow Allison Duettmann:
About Foresight Institute: Foresight Institute is a think tank and public interest organization focused on transformative future technologies.
Gerald Proehl
Board of Directors of Auspex Pharmaceuticals
Gerry Proehl is the former President and CEO of Santarus, Inc. where he led the sale of that company to Salix in early 2014 for $2.6 billion. Prior to Santarus, Proehl was with Hoechst Marion Roussel for 14 years, where he served in various capacities, including Vice President of Global Marketing. While at Hoechst, he was responsible for marketing products in multiple therapeutic areas, including the central nervous system. Proehl holds a BS in education from the State University of New York at Cortland, an MA in exercise physiology from Wake Forest University, and an MBA from Rockhurst College. Chair of the Nominating and Governance Committee, Member of the Compensation Committee
Follow Gerald Proehl:
About Dermata Therapeutics: Auspex Pharmaceuticals is a deuteration company developing therapeutics for depressive disorders.
Marie Knowles
Member of the Board of Directors, Chair of the Audit Committee & Member of the Finance Committee of McKesson
Marie Knowles retired from Atlantic Richfield Company (“ARCO”) in 2000 and was Executive Vice President and Chief Financial Officer from 1996 until 2000 and a director from 1996 until 1998. She joined ARCO in 1972. Marie Knowles is also a member of the Board of Trustees of the Fidelity Funds. She has been a director of the Company since March 2002. She is Chair of the Audit Committee and a member of the Finance Committee.
Follow Marie Knowles:
About : McKesson distributes medical supplies, information technology, and care management products and services.
Kenneth Kelley
Co-Founder, CEO & Director of PaxVax
Mr. Kelley co-founded PaxVax in early 2007 and serves as the Company’s Chief Executive Officer and Executive Chairman. Mr. Kelley brings to PaxVax thirty years of experience in biotechnology (IntraBiotics, Integrated Genetics), venture capital (K2 BioVentures, Latterell Venture Partners, Institutional Venture Partners), and strategic management (McKinsey & Company). During his career, Mr. Kelley has funded 36 early stage biotechnology and medical device companies, fifteen of which became public. As founder/CEO and Chairman of IntraBiotics Pharmaceuticals, Inc., he raised over $200M and took the company public in 2000 (NASDAQ: IBPI). Mr. Kelley also serves as Chairman of the Board for Halozyme (NASDAQ: HALO) and Fluxion Biosystems. Mr. Kelley earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University.
Follow Kenneth Kelley:
About PaxVax: PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Stella Sarraf
Chief Executive Officer, Founder & Director of Amydis, Inc.
Dr. Sarraf founded Amydis in 2013 after seeing a clinical need for diagnostics that can enable early detection of neurodegenerative diseases. She brings a blend of large pharmaceutical operational expertise, venture investment background and entrepreneurship to Amydis. Dr. Sarraf is viewed as a visionary with a deep understanding of “cradle to grave” and the necessary components to achieve success from product concept through to commercialization. Previously, she spent 10 years in Venture Capital at Foresite Capital Management and Prospect Venture Partners, both growth capital healthcare funds with over $1B dollars in assets under management. Some of the successful investments and exits by Foresite with Dr. Sarraf’s involvement included Wavetec Vision (sold to Alcon in 2014), Ambit Biosciences (acquired by Daiichi Sankyo in 2014 for $410M) and Auspex Pharmaceuticals (sold to Teva for $3.5B in 2015). At Prospect, she performed scientific, regulatory and commercial diligence on more than 400 investment opportunities from companies in therapeutic and diagnostic areas including the neurological and cognitive disorder space. Earlier in her career, Dr. Sarraf worked at Merck Research Laboratories in Rahway, New Jersey as a senior research chemist responsible for creating the chemical synthesis of a novel drug for translation from the bench to production scale.
Follow Stella Sarraf:
About Amydis, Inc., Scientific Consulting, Spinogenix, Spinogenix: A pharmaceutical company focused on developing innovative chemistry to detect diseases that involve the presence of amyloid proteins.
Nick Arora
Director, Medical Information of xCures
Nick A. Arora is an entrepreneur, investor and advisor within emerging technologies and health. He is Director, Medical Information at xCures an AI-based precision oncology platform that tightly integrates cancer research and care. He also serves as Chief Health Advisor of Rymedi, a health/life sciences company improving the process of capturing, tracking & sharing data to expand markets and improve health & wellness. Previously, Nick has been Chief Business Development Officer at Solaster, a consumer-driven health ecosystem creating global interoperability of decentralized, distributed health applications and blockchains. He was a founding member and Chief Strategy Officer at LINKCHAIN, a blockchain-enabled supply chain company where he led key strategic initiatives including the company’s partnership with GoChain. Nick has also served as Chief Business Officer and Health Lead at BlockRake, a premier capital markets consulting firm. Nick has lectured on blockchain, supply chain and health at Stanford University and has been the Co-Host of Blockchain in Health Care SF, the largest blockchain health meetup organization in Silicon Valley. An Ivy League graduate from Yale University and former Medical Doctor (M.D.) Candidate, Nick’s research at Johns Hopkins University has been published in top scientific journals across the world. He has also advised healthcare organizations globally and founded multiple businesses, including CrankOut, a health tech company that was featured in Entrepreneur.
Follow Nick Arora:
About xCures: xCures is an AI-based precision oncology platform that tightly integrates cancer research and care.
Hanlin Gao
Lab Director and Chief Scientific Officer of Fulgent Therapeutics
Hanlin (Harry) Gao, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G. is a founder of our genetic testing business, is our Lab Director and Chief Scientific Officer. Dr. Gao’s prior experience includes service as Lab Director of both the DNA Sequencing Core Laboratory and Clinical Molecular Diagnostics Laboratory at City of Hope from 2004 until 2013. Dr. Gao completed his clinical molecular genetics training fellowship and post-doctoral fellowship at Harvard Medical School in 2004 prior to joining City of Hope. Dr. Gao received an M.S. in Immunology and an M.D. from Peking University and Inner Mongolia University for Nationalities in China in 1993 and 1990, respectively, as well as a Ph.D. in Microbiology, Immunology and Medical Genetics from The Ohio State University in 2001. Dr. Gao is board certified in clinical molecular genetics by the American Board of Medical Genetics, is a Fellow of the American College of Medical Genetics and Genomics and serves as a team leader for laboratory inspections by CAP.
Follow Hanlin Gao:
About Fulgent Therapeutics: Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics.
Paul Stanley
Senior Director of Facilities of BioMarin Pharmaceutical
Follow Paul Stanley:
About BioMarin Pharmaceutical: BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Diane White
Exec. Director, Head of Global Project Management of BioMarin Pharmaceutical
Follow Diane White:
About BioMarin Pharmaceutical: BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Kelly Mabry
Director of Research & Development of Tangible Science
Follow Kelly Mabry:
About Tangible Science, VIC Technology Venture Development: Tangible Science is a developer of contact lenses designed to reduce lens discomfort in dry eye diseases.
William Rohn
Chairman of the Board of Directors of Pfenex
William Rohn, age 71, has served as a member of our Board of Directors since March 2012. William served as Chief Operating Officer of Biogen Idec, the successor company to IDEC Pharmaceuticals, a biotechnology company, from 2003 until 2005. From 1998 until 2003, William was President and Chief Operating Officer of IDEC Pharmaceuticals, a biotechnology company. William joined IDEC in 1993 as Senior Vice President, Commercial and Corporate Development and was appointed Senior Vice President, Commercial Operations in 1996. From 1985 until 1993, William was employed by Adria Laboratories, a pharmaceutical company that has since been acquired by Pfizer Inc., most recently as Senior Vice President of Sales and Marketing. Before moving to the fledgling biotech industry in its early days, William spent approximately 25 years in the pharmaceutical sector in a variety of commercial operating roles of increasing responsibility with such companies as Abbott Laboratories, Bristol-Myers Squibb Co., and Adria Laboratories (now part of Pfizer). He is Chairman of the Board at Pfenex Inc., a developer of biosimilar protein pharmaceuticals. William’s knowledge of our industry and his prior and current experience as a senior officer and director of other healthcare companies contributed to our conclusion that he should serve as a director.
Follow William Rohn:
About : Pfenex develops biosimilar therapeutics and novel vaccines for the treatment and prevention of critical human health issues.
Ron Cohen
Senior Director of NantWorks
Technology leader and entrepreneur. Inventor of mobile visual search (image recognition via mobile phones). Founded 2 mobile technology companies. Extensive experience in technology development, system/project architecture and management, software development, mobile, aerospace, entrepreneurship, and business development, in organizations ranging from startups to NASA and DoD.
Follow Ron Cohen:
About NantWorks: NantWorks combines semiconductor technology, supercomputing and advanced networks to improve healthcare, commerce and digital entertainment.
Brian Freed
Managing Director, Executive Officer of Caricord
Executive Director Dr. Freed has over 30 years of experience and over 80 publications in the fields of stem cell banking and histocompatibility. He is a member of the American Society for Histocompatibility and Immunogenetics, AABB, the American Society of Transplantation, and the American Society for Blood and Marrow Transplantation. Dr. Freed is a diplomate of the American Board of Histocompatibility and Immunogenetics.
Follow Brian Freed:
About Caricord: CariCord is an umbilical cord blood bank that is both public and private while also holding rigorous FDA licensure.
Bob Hayden
Architecture Director, Research and Development Informatics of Amgen
Architecture Director, Research and Development Informatics at Amgen.
Follow Bob Hayden:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
Art Hewig
Executive Director, Pivotal Drug Substance Process Development of Amgen
Art Hewig is a Director of Process Development at Amgen where he leads an integrated group that is designed to deliver end-to-end drug substance processes that robustly transfer to Amgen’s commercial network. Prior to the role Art was heading Purification Process Development at Amgen. Art has been with Amgen since 2002, where his initial focus was developing purification processes for early and late stage molecules. During this time he developed and implemented real time PAT technologies utilizing light scattering and as well as connected downstream processing. Art holds a PhD in Chemical Engineering from Carnegie Mellon University.
Follow Art Hewig:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
Kathryn West
Advocacy Director of Amgen
Kathryn A. West is the Advocacy Director of Amgen Inc. In her role, Ms. West works closely with Amgen’s Global Government Affairs (GGA) office in Washington D.C. to develop business plans, strategies and relationships with advocacy partners and organizations. Ms. West has been an active member of the Oncology Nursing Society (ONS) since 1990 and has been recognized as an Oncology Certified Nurse (OCN) since 1992. For ten years, she held positions as an oncology nurse and an administrative director of Oncology Services at UCLA Medical Center, where she worked alongside world-renowned cancer researchers and physicians and managed a staff of over 170 health care providers. In collaboration with a dedicated team, Ms. West led the effort to develop and implement the Medical Center’s first Oncology Intermediate Care Unit. Ms. West also partnered with Kaiser Permanente to develop and implement the Urban HealthCare Project which provides healthcare to the underserved and uninsured population of South Central Los Angeles. She received her Bachelor of Science in Nursing from the University of North Carolina at Chapel Hill and a Master of Science from the University of California at Los Angeles.
Follow Kathryn West:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
Adi Rapaka
Director of Commercial Information Management of Amgen
Follow Adi Rapaka:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
Rey Chern
Engineering Director, Drug Prodcut Technology of Amgen
Follow Rey Chern:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
Rey Chern
Engineering Director, Drug Prodcut Technology of Amgen
Follow Rey Chern:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
James S. Marcelli
President & COO & Director of Lightwave Logic
Mr. Marcelli has served as President, CEO and director of Lightwave Logic since August 2008. He is responsible for the day-to-day operations of the company and its progress toward a fully functioning commercial enterprise. Over the last twenty years, Mr. Marcelli has served as the president and chief executive officer of multiple start-up and growth companies in high tech manufacturing and business services, including two companies that were founded by him. In addition, he has held senior management positions with several companies including Teradyne Corporation and Sanmina Corporation. Throughout his career, he has held positions in Engineering, Sales, Marketing, Operations and Finance. Mr. Marcelli has served on the boards of several non-profit corporations and also served on the Advisory Board of the University of Colorado, Colorado Springs Engineering School.
Follow James S. Marcelli:
About Lightwave Logic: Lightwave Logic is a research and development company focused on developing application-specific electro-optic polymers.
Tomohiro Takano
Representative Director, CEO, and Founder of Genomelink
Tomo started his career as a member of the founding team of Impact Hub Tokyo. Through his involvement in establishing this social enterprise community center and business incubator, he honed his start-up business acumen and connected with domestic and international entrepreneurs. In his next role as the business development manager of G-TAC, a genomic corporate venture of M3, Inc., he leads major operations in building a genomic healthcare platform within the primary online network of physicians in Japan. His belief in the potential of the genome in widespread applications led to the founding of AWAKENS, Inc. in 2017.
Follow Tomohiro Takano:
About Genomelink: Genomelink is a platform where people discover more with their DNA data and help businesses build, market, and do research with it.